Histidine-Rich Glycoprotein as a novel severity biomarker for sepsis: application to early treatment

Histidine-Rich Glycoprotein as a novel severity biomarker for sepsis: application to early treatment - HRG as a novel severity biomarker for sepsis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030037

Enrollment

200

Registered

2018-02-01

Start date

2018-08-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients newly diagnosed sepsis: Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, and organ dysfunction can be identified as an acute change in total SOFA score 2 points or more consequent to the infection.

Exclusion criteria

Exclusion criteria: Pregnancy and Under 20 years old

Design outcomes

Primary

Measure	Time frame
We confirm the time change of HRG levels in patients with sepsis, and examine the association with a clinical course and a prognosis.	—

Secondary

Measure	Time frame
We examine the change of HRG levels by the cause of sepsis.	—

Countries

Japan

Contacts

Public ContactNaoya Kawanoue

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Anesthesiology and Resuscitology

nao.kawa@s.okayama-u.ac.jp086-235-7327

Outcome results